Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
MTNB vs EQ: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
EQ Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–2 Matrix Metrics)
EQ Overall Winner
6-Pillar Tally: MTNB 1 – 4 EQ (1 Tie)
Matrix Metrics: MTNB 2 – 6 EQ
As of Nov 19, 2026, Equillium, Inc. (EQ) is the stronger overall head-to-head candidate over Matinas BioPharma Holdings, Inc. (MTNB) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MTNB carries a Unified Composite Score of 54.6/100 (HOLD) at $0.81 (N/M Forward P/E, 0.0% operating margin), whereas EQ carries 48.0/100 (HOLD) at $1.12 (1.5x Forward P/E, 0.0% operating margin).
- Composite vs. Pillar Nuance: While MTNB currently prints a higher short-term Unified Composite Score (54.6/100 HOLD vs. EQ 48.0/100 HOLD), EQ captures the overall institutional head-to-head verdict (6–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (-52.3% vs. -100.0% YoY).
- Technical & Structure Timing Caution: MTNB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 33.0); meanwhile EQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About MTNB vs EQ
MTNB
Matinas BioPharma Holdings, Inc.
$0.81
-10.98% 1D
Market Cap
$979,904
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
-7.20β · 147% Vol
Unified Composite Score
54.6
HOLD
Tech 53.0
Fund 58.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
EQ
Head-to-Head Winner
Equillium, Inc. Common Stock
$1.12
+1.82% 1D
Market Cap
$90.6M
TTM Revenue
$4.4M
Forward P/E
1.5x
Beta / 30D Vol
1.53β · 93% Vol
Unified Composite Score
48.0
HOLD
Tech 30.0
Fund 51.0
Flow 63.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (MTNB 1 – 4 EQ)
1. Valuation Multiples
EQ
Forward P/E
N/M
1.5x
Trailing P/E
N/M
1.5x
PEG Ratio
N/M
N/M
EV / Revenue
N/M
7.7x
2. Growth & Scale
EQ
Revenue Growth (YoY)
-100.0%
-52.3%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$4.4M
Market Cap
$979,904
$90.6M
3. Profitability & Quality
EQ
Gross Margin
N/A
100.0%
Operating Margin
0.0%
0.0%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-147.5%
-59.0%
4. Balance Sheet & Cash Flow
MTNB
Cash Generation (TTM)
N/A
-$20M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$1.2M Net Cash
$57M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
EQ
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
261.3% (100th %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: MTNB (2) vs EQ (6)| Institutional Metric | MTNB | EQ | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $979,904 | $90.6M | EQ | |
| Trailing P/E Ratio | N/M | 1.5x | EQ | |
| Forward P/E Ratio | N/M | 1.5x | EQ | |
| Revenue Growth (YoY) | -100.0% | -52.3% | EQ | |
| Operating Margin (TTM) | 0.0% | 0.0% | Tie | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -147.5% | -59.0% | EQ | |
| 52-Week Range Position | 22% ($0–$3) | 11% ($1–$4) | MTNB | |
| Beta / 30D Volatility | -7.20β · 147% Vol | 1.53β · 93% Vol | EQ | |
| Unified Institutional Score | 54.6 / 100 (HOLD) | 48.0 / 100 (HOLD) | MTNB | |
| Trailing 12M Revenue (USD) | N/A | $4.4M | Scale | |
| Gross Profit Margin (TTM) | N/A | 100.0% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 7.7x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | N/A ($1.2M Net Cash) | -$20M ($57M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
EQ +25.57 pp
3M Horizon
MTNB +359.01 pp
6M Horizon
MTNB +70.25 pp
1Y Horizon
EQ +43.35 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MTNB Revenue | EQ Revenue | MTNB Op. Margin | EQ Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2017 | $0M | N/A | -11024.6% | N/A | MTNB |
| FY2018 | $0M | N/A | -12230.9% | N/A | MTNB |
| FY2019 | $0M | N/A | -21067.4% | N/A | MTNB |
| FY2020 | $0M | N/A | -15288.4% | N/A | MTNB |
| FY2021 | $0M | N/A | -74954.5% | N/A | MTNB |
| FY2022 | $0M | $20M | -771.3% | -393.9% | EQ |
| FY2023 | $0M | $40M | -2168.4% | -40.2% | EQ |
| FY2024 | N/A | $40M | N/A | -20.1% | EQ |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
MTNB
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact MTNB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
EQ
UNCLASSIFIED
Current IV
261.3%
IV Percentile
100th %ile
Put/Call OI Skew
N/A
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact EQ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
MTNB Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
EQ Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ MTNB vs EQ Key Questions & Quantitative Answers
As of Nov 19, 2026, Equillium, Inc. (EQ) is the stronger overall head-to-head candidate over Matinas BioPharma Holdings, Inc. (MTNB) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MTNB carries a Unified Composite Score of 54.6/100 (HOLD) at $0.81 (N/M Forward P/E, 0.0% operating margin), whereas EQ carries 48.0/100 (HOLD) at $1.12 (1.5x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While MTNB currently prints a higher short-term Unified Composite Score (54.6/100 HOLD vs. EQ 48.0/100 HOLD), EQ captures the overall institutional head-to-head verdict (6–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (-52.3% vs. -100.0% YoY). Technical & Structure Timing Caution: MTNB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 33.0); meanwhile EQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
EQ leads the Growth & Scale pillar: MTNB posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with EQ at -52.3% YoY revenue growth and +0.0% YoY earnings growth on $4.4M TTM revenue (100.0% gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2017 to FY2024), MTNB cumulative revenue shifted N/A while EQ shifted +100.0%. In operating R&D and SG&A reinvestment, MTNB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EQ.
EQ screens cheaper on headline valuation multiples. MTNB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas EQ trades at 1.5x Forward P/E, 1.5x Trailing P/E, N/M PEG, and 7.7x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MTNB (-147.5% ROE) versus EQ (-59.0% ROE) capital efficiency.
In options market volatility and institutional positioning, MTNB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-7.20β · 147% Vol realized risk). By comparison, EQ carries 261.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.53β · 93% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
EQ vs MTNB · Reverse Pair
MTNB vs VTVT
· Sector Peer
EQ vs ECOR
· Sector Peer
EQ vs CRVS
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking